0

Generation of Clinical-Grade CD19-specific CAR-modified CD8+ Memory Stem Cells for the Treatment of Human B-cell Malignancies

Marianna Sabatino, Jinhui Hu, Michele Sommariva, Sanjivan Gautam, Vicki Fellowes, James D Hocker, Sean Dougherty, Haiying Qin, Christopher A Klebanoff, Terry J Fry, Ronald E Gress, James N Kochenderfer, etc.

Blood. 2016 Jul 28;128(4):519-28.

PMID: 27226436

Abstract:

Long-lived, self-renewing, multipotent T memory stem cells (TSCM) can trigger profound and sustained tumor regression but their rareness poses a major hurdle to their clinical application. Presently, clinically compliant procedures to generate relevant numbers of this T-cell population are undefined. Here, we provide a strategy for deriving large numbers of clinical-grade tumor-redirected TSCM starting from naive precursors. CD8(+)CD62L(+)CD45RA(+) naive T cells enriched by streptamer-based serial-positive selection were activated by CD3/CD28 engagement in the presence of interleukin-7 (IL-7), IL-21, and the glycogen synthase-3β inhibitor TWS119, and genetically engineered to express a CD19-specific chimeric antigen receptor (CD19-CAR). These conditions enabled the generation of CD19-CAR-modified CD8(+) TSCM that were phenotypically, functionally, and transcriptomically equivalent to their naturally occurring counterpart. Compared with CD8(+) T cells generated with clinical protocols currently under investigation, CD19-CAR-modified CD8(+) TSCM exhibited enhanced metabolic fitness and mediated robust, long-lasting antitumor responses against systemic acute lymphoblastic leukemia xenografts. This clinical-grade platform provides the basis for a phase 1 trial evaluating the activity of CD19-CAR-modified CD8(+) TSCM in patients with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP601514196-B TWS119 TWS119 601514-19-6 Price
qrcode